DelveInsight’s “Fibromyalgia Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the Fibromyalgia pipeline landscapes. It comprises Fibromyalgia pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Fibromyalgia therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Fibromyalgia pipeline products.
Some of the key takeaways of the Fibromyalgia Pipeline Report
-
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Forest Pharmaceuticals, Pfizer Pharmaceuticals, Innovativemed concepts, Aptinyx, Astellas Pharma, etc., are developing therapies for the treatment of Fibromyalgia.
-
Emerging therapies such as Savella, LYRICA, IMC-1, NYX-2925, ASP0819, are expected to have a significant impact on the Fibromyalgia market in the coming years.
-
IMC-1 (Innovativemed concepts) is a novel combination antiviral treatment that is designed to suppress the herpes virus. The company is currently planning to initiate a phase III study for the management of Fibromyalgia.
Get an overview of pipeline landscape @ Fibromyalgia Clinical Trials Analysis
Fibromyalgia is a disease in which the member states are widespread musculoskeletal pain accompanied by fatigue, problems with sleep, memory, and mood. Researchers believe that fibromyalgia increases the sensation of pain, the effects in the brain and the spinal cord treatment is painful and does not cause the pain signals.
Fibromyalgia Emerging Drugs
-
Savella by Forest Pharmaceuticals
-
LYRICA by Pfizer Pharmaceuticals
-
IMC-1 by Innovativemed concepts
-
NYX-2925 by Aptinyx
-
ASP0819 by Astellas Pharma
-
And others.
Scope of Fibromyalgia Pipeline Drug Insight
-
Coverage: Global
-
Major Players: Forest Pharmaceuticals, Pfizer Pharmaceuticals, Innovativemed concepts, Aptinyx, Astellas Pharma, and others.
-
Pipeline Therapies: Savella, LYRICA, IMC-1, NYX-2925, ASP0819, and others.
Table of Contents
|
1 |
Fibromyalgia Report Introduction |
|
2 |
Fibromyalgia Executive Summary |
|
3 |
Fibromyalgia Overview |
|
4 |
Fibromyalgia- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Fibromyalgia Pipeline Therapeutics |
|
6 |
Fibromyalgia Late Stage Products (Phase II/III) |
|
7 |
Fibromyalgia Mid Stage Products (Phase II) |
|
8 |
Fibromyalgia Early Stage Products (Phase I) |
|
9 |
Fibromyalgia Preclinical Stage Products |
|
10 |
Fibromyalgia Therapeutics Assessment |
|
11 |
Fibromyalgia Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Fibromyalgia Key Companies |
|
14 |
Fibromyalgia Key Products |
|
15 |
Fibromyalgia Unmet Needs |
|
16 |
Fibromyalgia Market Drivers and Barriers |
|
17 |
Fibromyalgia Future Perspectives and Conclusion |
|
18 |
Fibromyalgia Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
Get a customized pipeline report @ Fibromyalgia Drugs Pipeline Report
Related Reports:
Fibromyalgia Market
DelveInsight’s Fibromyalgia – Market Insights, Epidemiology, and Market Forecast-2030 report deliver an in-depth understanding of the Fibromyalgia, historical and forecasted epidemiology as well as the Fibromyalgia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Fibromyalgia Epidemiology
DelveInsight’s ‘Fibromyalgia- Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Fibromyalgia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/